Novavax Inc.'s Ebola vaccine candidate is facilitating the antibody protection in healthy volunteers in an early clinical study, Bloomberg Business reported Tuesday.
The head of research at the company, Greg Glenn, says these are promising results and that in pre-clinical trials monkeys that had a similar response to the vaccine were protected from infection.
According to the company, the vaccine is being reported as being well-tolerated among 230 healthy adult, volunteers in Australia. The company reports that the only side effect is a minor headache among some people.
The outbreak of the Ebola virus in West Africa is considered to be the largest outbreak since the discovery of the virus in 1976. Through Sunday, the World Health Organization has reported 11,284 deaths caused by the virus and complications, with 27,742 suspected and probable cases. Sierra Leone, Liberia and Guinea are the most affected countries.
Bloomberg reports that Novavax shares have increased by more than double over the course of this year on the New York Stock Exchange, closing Tuesday at $12.32.